Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495576 | 0.84 | PGR (0.43) | PGRAPOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL29406168 | 0.81 | APOBEC3G (0.62) | PSMB8APOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL29533085 | 0.81 | KDM4E (0.53) | PGRAPOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL29361254 | 0.75 | TRAP1 (0.46) | PGRAPOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL6540445 | 0.71 | PGR (1.00) | PGRAPOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL29349517 | 0.67 | TRAP1 (0.43) | ALDH1A1MEN1KMT2AMPOTDP1 | |
| SCHEMBL5201783 | 0.67 | PDE2A (0.47) | ALDH1A1KDM4E | |
| SCHEMBL29360207 | 0.67 | MAPK1 (0.42) | PSMB8MEN1KMT2AMPOTDP1 | |
| SCHEMBL31395550 | 0.66 | KMT2A (0.53) | PGRAPOBEC3GALDH1A1MEN1KMT2A | |
| SCHEMBL29351347 | 0.65 | TDP1 (0.38) | APOBEC3GALDH1A1MEN1KMT2AMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260126440-A1 | METHODS FOR MEASURING LYMPHOCYTE ACTIVITY | KITE PHARMA INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4680771-A1 | IMPACT OF TUMOR MICROENVIRONMENT ON EFFICACY OF IMMUNOTHERAPY | Kite Pharma, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12528856-B2 | Chimeric cytokine receptors comprising TGF β binding domains | ALLOGENE THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-3505623-B1 | CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING ANTIGEN PRESENT BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS | CELLECTIS (FR) | 2025-12-24 | — | — | EP | claimed |
| US-20250375480-A1 | Methods for Generating Engineered Lymphocytes | KITE PHARMA INC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250367236-A1 | ENGINEERED IMMUNE CELLS | UNIKUM THERAPEUTICS APS (DK) | 2025-12-04 | — | — | US | claimed |
| WO-2025245494-A1 | TUMOR-TARGETED SPLIT IL12 RECEPTOR AGONISTS | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250297219-A1 | METHODS FOR GENERATING ENGINEERED LYMPHOCYTES WITH ENRICHED T MEMORY STEM CELLS | KITE PHARMA, INC. | 2025-09-25 | — | — | US | claimed |
| US-20250290154-A1 | PREDICTIVE MARKERS FOR IMMUNOTHERAPY | GILEAD SCIENCES, INC. | 2025-09-18 | — | — | US | claimed |
| EP-4615978-A1 | METHODS AND COMPOSITIONS FOR CELL-SURFACE CO-LOCALIZATION OF CHIMERIC PROTEINS | Senti Biosciences, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-11454636-B2 | Procedure of predicting type 2 diabetes development through analysis of N-glycans attached to the plasma proteins of a healthy person | GENOS D.O.O. (HR) | 2022-09-27 | — | — | US | claimed |
| CN-115023444-A | Novel IL2 agonists and methods of use thereof | 再生元制药公司 | 2022-09-06 | — | — | CN | claimed |
| CN-114966011-A | Test strip for detecting HIV-1 and HIV-2 antibodies in urine by colloidal gold method | 杭州协合医疗用品有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220265721-A1 | TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T CELLS | KITE PHARMA INC (US) | 2022-08-25 | — | — | US | claimed |
| US-11357796-B2 | Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells | KITE PHARMA, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20220169694-A1 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | KITE PHARMA, INC. | 2022-06-02 | — | — | US | claimed |
| CN-109725153-B | Homogeneous phase immunoassay method and application thereof | 科美诊断技术股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114502957-A | Kit and method for detecting HIV antibodies | 深圳迈瑞生物医疗电子股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022063201-A1 | COMPOUND AND METHOD FOR ENHANCING T-CELL FUNCTION | 中国科学院动物研究所 | 2022-03-31 | — | — | WO | claimed |
| CN-109477842-B | Prediction of the progression of type 2 diabetes by analysis of N-glycoprotein in healthy human plasma proteins | 詹诺斯公司 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528856-B2 | Chimeric cytokine receptors comprising TGF β binding domains | IL2RA, IL15RA, LIFR | PGR 2006/4885PSMB8 1074/4885APOBEC3G 1356/4885 |
| US-20260126440-A1 | METHODS FOR MEASURING LYMPHOCYTE ACTIVITY | CD14, CD47, CD4 | PGR 1709/4885PSMB8 3572/4885APOBEC3G 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.